A Peek Behind the Medicare Drug Price Negotiation Curtain

Health Affairs' Jeff Byers welcomes Senior
Editor Ellen Bayer to the program to discuss the
ongoing progress of the Inflation Reduction Act of 2022, how it's
being implemented, and how we can best evaluate the Medicare Drug
Price Negotiation Program.


Health Affairs will be hosting a virtual Journal Club event on
Tuesday, August 27, entitled "Coverage of Anti-Obesity Medicines
Could Increase Medicare Spending By Billions" featuring author
Benedic Ippolito discussing his recent paper on
the topic.


This event is exclusive to our Health
Affairs Insiders.


If you have yet to become an Insider, sign up today to stay
up-to-date on what health care experts are thinking and talking
about.


Related Articles:


Is It Working? Evaluating The First Round Of Medicare Drug
Price Negotiations (Health Affairs)

FACT SHEET: Biden-⁠Harris Administration Announces New, Lower
Prices for First Ten Drugs Selected for Medicare Price
Negotiation to Lower Costs for Millions of Americans

The First-Ever Government Negotiation Process For Drugs Has
Finished, But The Politics Are Ongoing (Health Affairs Forefront)

FAQs about the Inflation Reduction Act’s Medicare Drug Price
Negotiation Program (KFF)

Explaining the Prescription Drug Provisions in the Inflation
Reduction Act (KFF)